172 related articles for article (PubMed ID: 9266099)
1. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
Crump M; Sawka CA; DeBoer G; Buchanan RB; Ingle JN; Forbes J; Meakin JW; Shelley W; Pritchard KI
Breast Cancer Res Treat; 1997 Jul; 44(3):201-10. PubMed ID: 9266099
[TBL] [Abstract][Full Text] [Related]
2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
3. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.
Sawka CA; Pritchard KI; Shelley W; DeBoer G; Paterson AH; Meakin JW; Sutherland DJ
Breast Cancer Res Treat; 1997 Jul; 44(3):211-5. PubMed ID: 9266100
[TBL] [Abstract][Full Text] [Related]
4. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.
Boccardo F; Rubagotti A; Perrotta A; Amoroso D; Balestrero M; De Matteis A; Zola P; Sismondi P; Francini G; Petrioli R
Ann Oncol; 1994 Apr; 5(4):337-42. PubMed ID: 8075030
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Emens LA; Davidson NE
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
[TBL] [Abstract][Full Text] [Related]
6. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
7. The role of ovarian ablation in the management of breast cancer.
Wirk B
Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy.
Kwon AH; Yamada O; Uetsuji S; Matsui Y; Kamiyama Y
Surg Laparosc Endosc; 1997 Jun; 7(3):223-7. PubMed ID: 9194283
[TBL] [Abstract][Full Text] [Related]
9. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
[TBL] [Abstract][Full Text] [Related]
10. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
11. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
12. Role of adjuvant endocrine therapy in early-stage breast cancer.
Muss HB
Semin Oncol; 2001 Aug; 28(4):313-21. PubMed ID: 11498825
[TBL] [Abstract][Full Text] [Related]
13. Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?
Bilimoria MM; Jordan VC
Semin Surg Oncol; 1996; 12(5):339-45. PubMed ID: 8873322
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
15. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study.
Hughes LL; Gray RJ; Solin LJ; Robert NJ; Martino S; Tripathy D; Ingle JN; Wood WC; ; ; ;
Cancer; 2004 Sep; 101(5):969-72. PubMed ID: 15329905
[TBL] [Abstract][Full Text] [Related]
17. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI
Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
[TBL] [Abstract][Full Text] [Related]
18. Long-term consequences of ovarian ablation for premenopausal breast cancer.
Kwon JS; Pansegrau G; Nourmoussavi M; Hammond G; Carey MS
Breast Cancer Res Treat; 2016 Jun; 157(3):565-73. PubMed ID: 27236562
[TBL] [Abstract][Full Text] [Related]
19. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
20. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
Prowell TM; Davidson NE
Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
